Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 6 (June)

1. Body silhouette, menstrual function at adolescence and breast cancer risk in the E3N cohort study.
   Br J Cancer, 92(11): 2042-8. [Abstract] [Full-text]
2. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
   Br J Cancer, 92(11): 1989-96. [Abstract] [Full-text]
3. Quantifying estrogen and progesterone receptor expression in breast cancer by digital imaging.
   J Histochem Cytochem, 53(6): 753-62. [Abstract] [Full-text]
4. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status.
   J Natl Cancer Inst, 97(11): 805-12. [Abstract] [Full-text]
5. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
   J Natl Cancer Inst, 97(11): 798-804. [Abstract] [Full-text]
6. An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent.
   Bioorg Med Chem, 13(13): 4315-22. [Abstract] [Full-text]
7. Histopathological findings in surgical specimens obtained from reduction mammaplasties.
   Breast, 14(3): 242-8. [Abstract] [Full-text]
8. Concentration of histamine in serum and tissues of the primary ductal breast cancers in women.
   Breast, 14(3): 236-41. [Abstract] [Full-text]
9. Immunohistochemical evaluation of endothelial nitric oxide synthase expression in primary breast cancer.
   Breast, 14(3): 230-5. [Abstract] [Full-text]
10. Audit of local recurrence rates following 'ultra'-conservative surgery for invasive breast cancer--a boost to the breast?
    Breast, 14(3): 224-9. [Abstract] [Full-text]
11. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study.
    Breast, 14(3): 201-8. [Abstract] [Full-text]
12. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.
    Breast, 14(3): 192-200. [Abstract] [Full-text]
13. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer.
    Breast, 14(3): 181-91. [Abstract] [Full-text]
14. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
    Br J Cancer, 92(11): 2049-58. [Abstract] [Full-text]
15. Alcohol dehydrogenase 1B (ADH1B) genotype, alcohol consumption and breast cancer risk by age 50 years in a German case-control study.
    Br J Cancer, 92(11): 2039-41. [Abstract] [Full-text]
16. Breast conservation after neoadjuvant chemotherapy.
    Ann Surg Oncol, 12(6): 480-7. [Abstract] [Full-text]
17. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer.
    Ann Surg Oncol, 12(6): 488-96. [Abstract] [Full-text]
18. Correlation between concordance of tracers, order of harvest, and presence of metastases in sentinel lymph nodes with breast cancer.
    Ann Surg Oncol, 12(6): 497-503. [Abstract] [Full-text]
19. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
    J Cell Physiol, 204(2): 678-86. [Abstract] [Full-text]
20. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
    J Cell Physiol, 204(2): 463-9. [Abstract] [Full-text]
21. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
    Biol Blood Marrow Transplant, 11(6): 472-83. [Abstract] [Full-text]
22. The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer.
    Biol Blood Marrow Transplant, 11(6): 455-64. [Abstract] [Full-text]
23. Adjuvant docetaxel for node-positive breast cancer.
    N Engl J Med, 352(22): 2302-13. [Abstract] [Full-text]
24. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
    Clin Cancer Res, 11(11): 4083-9. [Abstract] [Full-text]
25. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Clin Cancer Res, 11(11): 4003-11. [Abstract] [Full-text]
26. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Cancer Res, 65(11): 4929-38. [Abstract] [Full-text]
27. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Cancer Res, 65(11): 4799-808. [Abstract] [Full-text]
28. A role for ADAM12 in breast tumor progression and stromal cell apoptosis.
    Cancer Res, 65(11): 4754-61. [Abstract] [Full-text]
29. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer.
    Cancer Res, 65(11): 4653-62. [Abstract] [Full-text]
30. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
    J Endocrinol, 185(3): 577-92. [Abstract] [Full-text]
31. Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Onkologie, 28(6): 339-44. [Abstract] [Full-text]
32. Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer.
    Onkologie, 28(6): 318-22. [Abstract] [Full-text]
33. Objective assessment of image quality in conventional and digital mammography taking into account dynamic range.
    Radiat Prot Dosimetry, 114(1): 380-2. [Abstract] [Full-text]
34. The effect of Medicare health care systems on women with breast and cervical cancer.
    Obstet Gynecol, 105(6): 1381-8. [Abstract] [Full-text]
35. Experience of sentinel node biopsy alone in early breast cancer without further axillary dissection in patients with negative sentinel node.
    ANZ J Surg, 75(5): 292-9. [Abstract] [Full-text]
36. Subsequent surgery after initial breast conserving surgery: a population based study.
    ANZ J Surg, 75(5): 260-4. [Abstract] [Full-text]
37. Two-dimensional mapping of underdosed areas using radiochromic film for patients undergoing total skin electron beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(3): 920-4. [Abstract] [Full-text]
38. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer.
    Int J Radiat Oncol Biol Phys, 62(3): 790-6. [Abstract] [Full-text]
39. Early ipsilateral breast tumor recurrences after breast conservation affect survival: an analysis of the National Cancer Institute randomized trial.
    Int J Radiat Oncol Biol Phys, 62(3): 785-9. [Abstract] [Full-text]
40. Detection and localization of occult lesions using breast magnetic resonance imaging: initial experience in a community hospital.
    Acad Radiol, 12(6): 728-38. [Abstract] [Full-text]
41. Spectral phase based medical image processing.
    Acad Radiol, 12(6): 708-21. [Abstract] [Full-text]
42. Estimation and comparison of CAD system performance in clinical settings.
    Acad Radiol, 12(6): 687-94. [Abstract] [Full-text]
43. Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells.
    FEBS Lett, 579(14): 3195-200. [Abstract] [Full-text]
44. 17-beta-estradiol activates maxi-K channels through a non-genomic pathway in human breast cancer cells.
    FEBS Lett, 579(14): 2995-3000. [Abstract] [Full-text]
45. Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Cancer Chemother Pharmacol, 56(2): 205-11. [Abstract] [Full-text]
46. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.
    Virchows Arch, 446(5): 489-96. [Abstract] [Full-text]
47. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast.
    Virchows Arch, 446(5): 532-6. [Abstract] [Full-text]
48. HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin.
    Cancer Chemother Pharmacol, 56(2): 212-20. [Abstract] [Full-text]
49. Interdigitating dendritic cell tumor with breast and cervical lymph-node involvement: a case report and review of the literature.
    Virchows Arch, 446(5): 546-54. [Abstract] [Full-text]
50. Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers.
    Psychooncology, 14(6): 478-91. [Abstract] [Full-text]
51. Exercise manages fatigue during breast cancer treatment: a randomized controlled trial.
    Psychooncology, 14(6): 464-77. [Abstract] [Full-text]
52. Anticipating loss and other temporal stressors predict traumatic stress symptoms among partners of metastatic/recurrent breast cancer patients.
    Psychooncology, 14(6): 492-502. [Abstract] [Full-text]
53. Predicting worries about health after breast cancer surgery.
    Psychooncology, 14(6): 503-9. [Abstract] [Full-text]
54. Increased risk of breast cancer development after diagnosis of salivary gland tumour.
    Eur J Cancer, 41(9): 1311-5. [Abstract] [Full-text]
55. Locoregional recurrence risks in elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy.
    Eur J Cancer, 41(9): 1267-77. [Abstract] [Full-text]
56. Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1567-70. [Abstract] [Full-text]
57. A comparison of bilateral breast cancers in BRCA carriers.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1534-8. [Abstract] [Full-text]
58. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1521-7. [Abstract] [Full-text]
59. Menstrual cycle characteristics and incidence of premenopausal breast cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1509-13. [Abstract] [Full-text]
60. Prenatal and perinatal correlates of adult mammographic breast density.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1502-8. [Abstract] [Full-text]
61. Energy balance and breast cancer risk.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1496-501. [Abstract] [Full-text]
62. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1418-23. [Abstract] [Full-text]
63. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
    Proc Natl Acad Sci U S A, 102(23): 8315-20. [Abstract] [Full-text]
64. Capecitabine plus docetaxel combination therapy.
    Cancer, 103(12): 2455-65. [Abstract] [Full-text]
65. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Genes Chromosomes Cancer, 43(4): 404-13. [Abstract] [Full-text]
66. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
    Cancer, 103(12): 2447-54. [Abstract] [Full-text]
67. Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II study.
    Chemotherapy, 51(2): 126-31. [Abstract] [Full-text]
68. Perceptions of insurance coverage for screening mammography among women in need of screening.
    Cancer, 103(12): 2473-80. [Abstract] [Full-text]
69. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up.
    Cancer, 103(12): 2481-4. [Abstract] [Full-text]
70. Polymorphism in the manganese superoxide dismutase (MnSOD) gene and risk of breast cancer in young women.
    J Cancer Res Clin Oncol, 131(7): 439-44. [Abstract] [Full-text]
71. Macrophage level is not affected by monocyte chemotactic protein-1 in invasive ductal breast carcinoma.
    J Cancer Res Clin Oncol, 131(7): 453-8. [Abstract] [Full-text]
72. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
    J Cancer Res Clin Oncol, 131(7): 420-8. [Abstract] [Full-text]
73. Women age < or = 35 years with primary breast carcinoma: disease features at presentation.
    Cancer, 103(12): 2466-72. [Abstract] [Full-text]
74. Localization of thymidine phosphorylase in breast cancer tissue.
    Med Mol Morphol, 38(2): 112-7. [Abstract] [Full-text]
75. Preliminary study of the lived experience of exercise for cancer survivors.
    Eur J Oncol Nurs, 9(2): 155-66. [Abstract] [Full-text]
76. Histiocytoid breast carcinoma: solid variant of invasive lobular carcinoma with decreased expression of both E-cadherin and CD44 epithelial variant.
    Pathol Int, 55(6): 353-9. [Abstract] [Full-text]
77. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
    Pathol Int, 55(6): 318-23. [Abstract] [Full-text]
78. Qualitative assessment of breast reconstruction in a specialist breast unit.
    ANZ J Surg, 75(6): 445-53; discussion 371-2. [Abstract] [Full-text]
79. Serum protein profiling by miniaturized solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry.
    Rapid Commun Mass Spectrom, 19(12): 1578-86. [Abstract] [Full-text]
80. Three-dimensional ultrasound for the assessment of breast lesions.
    Ultrasound Obstet Gynecol, 25(6): 592-8. [Abstract] [Full-text]
81. Metastasis from breast carcinoma to a tamoxifen-related endometrial polyp.
    Gynecol Oncol, 97(3): 946-8. [Abstract] [Full-text]
82. Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography.
    Gynecol Oncol, 97(3): 964-9. [Abstract] [Full-text]
83. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
    J Pathol, 206(3): 366-76. [Abstract] [Full-text]
84. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries.
    Hum Pathol, 36(5): 536-45. [Abstract] [Full-text]
85. Are risk factors for breast cancer associated with follow-up procedures in diverse women with abnormal mammography?
    Cancer Causes Control, 16(3): 245-53. [Abstract] [Full-text]
86. The impact of reproductive factors on breast cancer risk--the feasibility of using Swedish population-based registers to account for the effect of confounding in cohort studies.
    Cancer Causes Control, 16(3): 235-43. [Abstract] [Full-text]
87. The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1.
    Endocr Relat Cancer, 12(2): 393-406. [Abstract] [Full-text]
88. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
    Endocr Relat Cancer, 12(2): 383-92. [Abstract] [Full-text]
89. Tissue inhibitor of metalloproteinases-1 in breast cancer.
    Endocr Relat Cancer, 12(2): 215-27. [Abstract] [Full-text]
90. Breast-tissue sampling for risk assessment and prevention.
    Endocr Relat Cancer, 12(2): 185-213. [Abstract] [Full-text]
91. Perceptions of positive meaning and vulnerability following breast cancer: predictors and outcomes among long-term breast cancer survivors.
    Ann Behav Med, 29(3): 236-45. [Abstract] [Full-text]
92. Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo.
    Endocrinology, 146(7): 2885-94. [Abstract] [Full-text]
93. Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells.
    Endocrinology, 146(7): 3059-69. [Abstract] [Full-text]
94. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells.
    Endocrinology, 146(7): 3113-22. [Abstract] [Full-text]
95. The benefit of participating to clinical research.
    Breast Cancer Res Treat, 91(3): 279-81. [Abstract] [Full-text]
96. PKCdelta and mTOR interact to regulate stress and IGF-I induced IRS-1 Ser312 phosphorylation in breast cancer cells.
    Breast Cancer Res Treat, 91(3): 259-69. [Abstract] [Full-text]
97. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Breast Cancer Res Treat, 91(3): 249-58. [Abstract] [Full-text]
98. Racial disparities in treatment and survival of women with stage I-III breast cancer at a large academic medical center in metropolitan Detroit.
    Breast Cancer Res Treat, 91(3): 243-8. [Abstract] [Full-text]
99. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy.
    Breast Cancer Res Treat, 91(3): 217-25. [Abstract] [Full-text]
100. Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression.
     Breast Cancer Res Treat, 91(3): 207-15. [Abstract] [Full-text]
101. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers.
     Fam Cancer, 4(2): 195-206. [Abstract] [Full-text]
102. The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families.
     Fam Cancer, 4(2): 183-6. [Abstract] [Full-text]
103. Referrals of patients to colorectal cancer genetics services in south-east Scotland.
     Fam Cancer, 4(2): 151-61. [Abstract] [Full-text]
104. Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations.
     Fam Cancer, 4(2): 121-6. [Abstract] [Full-text]
105. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
     Fam Cancer, 4(2): 115-9. [Abstract] [Full-text]
106. Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort.
     Fam Cancer, 4(2): 105-13. [Abstract] [Full-text]
107. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
     Fam Cancer, 4(2): 97-103. [Abstract] [Full-text]
108. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
     Fam Cancer, 4(2): 89-96. [Abstract] [Full-text]
109. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
     Fam Cancer, 4(2): 77-84. [Abstract] [Full-text]
110. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast.
     Med Image Anal, 9(4): 315-29. [Abstract] [Full-text]
111. Enzymes that hydrolyze adenine nucleotides in platelets from breast cancer patients.
     Biochim Biophys Acta, 1740(3): 421-6. [Abstract] [Full-text]
112. Second reading of screening mammograms increases cancer detection and recall rates. Results in the Florence screening programme.
     J Med Screen, 12(2): 103-6. [Abstract] [Full-text]
113. Management of melanoma metastasis to the breast: case series and review of the literature.
     Br J Dermatol, 152(6): 1206-10. [Abstract] [Full-text]
114. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
     Biomed Pharmacother, 59(5): 253-63. [Abstract] [Full-text]
115. Tumor feature visualization with unsupervised learning.
     Med Image Anal, 9(4): 344-51. [Abstract] [Full-text]
116. The effect of a hyposmotic shock and purinergic agonists on K+(Rb+) efflux from cultured human breast cancer cells.
     Biochim Biophys Acta, 1712(1): 52-61. [Abstract] [Full-text]
117. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
     Eur J Cancer Care (Engl), 14(3): 272-81. [Abstract] [Full-text]
118. Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
     Eur J Cancer Care (Engl), 14(3): 267-71. [Abstract] [Full-text]
119. The experience of making treatment decisions for women with early stage breast cancer: a diagrammatic representation.
     Eur J Cancer Care (Engl), 14(3): 249-55. [Abstract] [Full-text]
120. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer.
     Eur J Cancer Care (Engl), 14(3): 211-22. [Abstract] [Full-text]
121. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells.
     J Proteome Res, 4(3): 674-89. [Abstract] [Full-text]
122. Mammographic density and the risk of breast cancer in Japanese women.
     Br J Cancer, 92(12): 2102-6. [Abstract] [Full-text]
123. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
     J Natl Cancer Inst, 97(12): 927-30. [Abstract] [Full-text]
124. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer.
     Mol Cancer Ther, 4(6): 1004-12. [Abstract] [Full-text]
125. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
     Mol Cancer Ther, 4(6): 956-67. [Abstract] [Full-text]
126. Undertreatment of obese women receiving breast cancer chemotherapy.
     Arch Intern Med, 165(11): 1267-73. [Abstract] [Full-text]
127. 'That's like chopping off a finger because you're afraid it might get broken': disease and illness in women's views of prophylactic mastectomy.
     Soc Sci Med, 61(5): 1106-17. [Abstract] [Full-text]
128. Metastatic mammary carcinomas with endocrine features: potential diagnostic pitfalls.
     Diagn Cytopathol, 33(1): 49-53. [Abstract] [Full-text]
129. The value of immunohistochemistry in sentinel lymph node histopathology in breast cancer.
     Br J Cancer, 92(12): 2201-5. [Abstract] [Full-text]
130. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.
     Br J Cancer, 92(12): 2206-15. [Abstract] [Full-text]
131. The impact of comorbidity on the survival of postmenopausal women with breast cancer.
     J Cancer Res Clin Oncol, 130(11): 664-70. [Abstract] [Full-text]
132. Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk.
     Clin Cancer Res, 11(12): 4620-6. [Abstract] [Full-text]
133. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
     Clin Cancer Res, 11(12): 4393-9. [Abstract] [Full-text]
134. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
     Clin Cancer Res, 11(12): 4372-81. [Abstract] [Full-text]
135. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
     Clin Cancer Res, 11(12): 4357-64. [Abstract] [Full-text]
136. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
     Cancer Res, 65(12): 5439-44. [Abstract] [Full-text]
137. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells.
     Cancer Res, 65(12): 5408-16. [Abstract] [Full-text]
138. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
     Cancer Res, 65(12): 5380-9. [Abstract] [Full-text]
139. DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells.
     Cancer Res, 65(12): 5337-43. [Abstract] [Full-text]
140. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer.
     Cancer Res, 65(12): 5325-36. [Abstract] [Full-text]
141. Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2.
     Cancer Res, 65(12): 5301-9. [Abstract] [Full-text]
142. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop.
     Cancer Res, 65(12): 5278-83. [Abstract] [Full-text]
143. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe.
     Cancer Res, 65(12): 5181-9. [Abstract] [Full-text]
144. Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis.
     Cancer Res, 65(12): 5112-22. [Abstract] [Full-text]
145. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
     Cancer Res, 65(12): 5054-62. [Abstract] [Full-text]
146. Association of genetic polymorphisms in the VEGF gene with breast cancer survival.
     Cancer Res, 65(12): 5015-9. [Abstract] [Full-text]
147. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction.
     Anal Biochem, 342(1): 69-77. [Abstract] [Full-text]
148. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
     Cancer Sci, 96(6): 333-9. [Abstract] [Full-text]
149. Modulation of cholinephosphotransferase activity in breast cancer cell lines by Ro5-4864, a peripheral benzodiazepine receptor agonist.
     Biochem Biophys Res Commun, 333(1): 35-41. [Abstract] [Full-text]
150. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells.
     Cell Death Differ, 12(7): 783-95. [Abstract] [Full-text]
151. Discovering molecular functions significantly related to phenotypes by combining gene expression data and biological information.
     Bioinformatics, 21(13): 2988-93. [Abstract] [Full-text]
152. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.
     Oncogene, 24(26): 4220-31. [Abstract] [Full-text]
153. Identification of 20 genes aberrantly methylated in human breast cancers.
     Int J Cancer, 116(3): 407-14. [Abstract] [Full-text]
154. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
     Int J Cancer, 116(3): 340-50. [Abstract] [Full-text]
155. Gene therapy vectors containing CArG elements from the Egr1 gene are activated by neutron irradiation, cisplatin and doxorubicin.
     Cancer Gene Ther, 12(7): 655-62. [Abstract] [Full-text]
156. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.
     Oncogene, 24(26): 4281-92. [Abstract] [Full-text]
157. Migration-stimulating factor displays HEXXH-dependent catalytic activity important for promoting tumor cell migration.
     Int J Cancer, 116(3): 378-84. [Abstract] [Full-text]
158. Cyclin D1 in breast cancer pathogenesis.
     J Clin Oncol, 23(18): 4215-24. [Abstract] [Full-text]
159. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals.
     J Clin Oncol, 23(18): 4192-7. [Abstract] [Full-text]
160. Breast cancer risk among Finnish cabin attendants: a nested case-control study.
     Occup Environ Med, 62(7): 488-93. [Abstract] [Full-text]
161. Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer.
     Health Serv Res, 40(3): 745-67. [Abstract] [Full-text]
162. A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
     Eur J Cancer, 41(10): 1409-15. [Abstract] [Full-text]
163. Quantification by affinity perfusion chromatography of phosphorylated BRCAl and BRCA2 proteins from tumor cells after lycopene treatment.
     J Chromatogr B Analyt Technol Biomed Life Sci, 821(2): 188-93. [Abstract] [Full-text]
164. Survival of young and older breast cancer patients in Geneva from 1990 to 2001.
     Eur J Cancer, 41(10): 1446-52. [Abstract] [Full-text]
165. Additional breast lesions in patients eligible for breast-conserving therapy by MRI: impact on preoperative management and potential benefit of computerised analysis.
     Eur J Cancer, 41(10): 1393-401. [Abstract] [Full-text]
166. Choline and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by laser scanning confocal fluorescence microscopy.
     Eur J Cancer, 41(10): 1453-9. [Abstract] [Full-text]
167. Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer.
     Eur J Cancer, 41(10): 1416-25. [Abstract] [Full-text]
168. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women.
     Gynecol Oncol, 98(1): 63-7. [Abstract] [Full-text]
169. Pathologic nipple discharge: surgery is imperative in postmenopausal women.
     Ann Surg Oncol, 12(7): 546-51. [Abstract] [Full-text]
170. A tat fusion protein-based tumor vaccine for breast cancer.
     Ann Surg Oncol, 12(7): 517-25. [Abstract] [Full-text]
171. The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer.
     Ann Surg Oncol, 12(7): 533-8. [Abstract] [Full-text]
172. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer.
     Ann Surg Oncol, 12(7): 539-45. [Abstract] [Full-text]
173. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
     Hum Genet, 117(2): 119-32. [Abstract] [Full-text]
174. Analysis of morphologic patterns of fine-needle aspiration of the breast to reduce false-negative results in breast cytology.
     Cancer, 105(3): 152-7. [Abstract] [Full-text]
175. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype.
     Ann Oncol, 16(7): 1094-9. [Abstract] [Full-text]
176. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
     Ann Oncol, 16(7): 1087-93. [Abstract] [Full-text]
177. Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma.
     J Biol Chem, 280(25): 23987-4003. [Abstract] [Full-text]
178. Angiosarcoma after breast-conserving therapy: fine-needle aspiration biopsy, immunocytochemistry, and clinicopathologic correlates.
     Cancer, 105(3): 145-51. [Abstract] [Full-text]
179. Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry.
     Cancer, 105(3): 178-83. [Abstract] [Full-text]
180. Metastatic vertebral tumor misdiagnosed in magnetic resonance imaging as benign degenerative bone marrow changes: a case report.
     Rheumatol Int, 25(5): 384-7. [Abstract] [Full-text]
181. Securin is overexpressed in breast cancer.
     Mod Pathol, 18(7): 985-90. [Abstract] [Full-text]
182. Predominance of high-grade pathway in breast cancer development of Middle East women.
     Mod Pathol, 18(7): 891-7. [Abstract] [Full-text]
183. Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography.
     Eur Radiol, 15(7): 1353-60. [Abstract] [Full-text]
184. Low-field versus high-field MRI in diagnosing breast disorders.
     Eur Radiol, 15(7): 1361-8. [Abstract] [Full-text]
185. Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
     Curr Med Res Opin, 21(5): 805-15. [Abstract] [Full-text]
186. Human breast cancer in vitro: matching histo-pathology with small-angle x-ray scattering and diffraction enhanced x-ray imaging.
     Phys Med Biol, 50(13): 2991-3006. [Abstract] [Full-text]
187. Increasing age does not affect efficacy of sentinel lymph node biopsy using smaller-sized technetium-99m tin colloids for breast cancer patients.
     Am J Surg, 190(1): 51-4. [Abstract] [Full-text]
188. The importance of location in determining breast conservation rates.
     Am J Surg, 190(1): 18-22. [Abstract] [Full-text]
189. Breast cancer in young Asian women: study on survival.
     ANZ J Surg, 75(7): 566-72. [Abstract] [Full-text]
190. Radiation doses to staff involved in sentinel node operations for breast cancer.
     Clin Physiol Funct Imaging, 25(4): 196-202. [Abstract] [Full-text]
191. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
     Oncogene, 24(27): 4362-9. [Abstract] [Full-text]
192. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis.
     Oncogene, 24(27): 4370-9. [Abstract] [Full-text]
193. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers.
     Carcinogenesis, 26(7): 1241-6. [Abstract] [Full-text]
194. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
     Mol Endocrinol, 19(7): 1740-51. [Abstract] [Full-text]
195. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.
     Mol Endocrinol, 19(7): 1765-78. [Abstract] [Full-text]
196. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
     Carcinogenesis, 26(7): 1296-306. [Abstract] [Full-text]
197. Small cell neuroendocrine carcinoma of the breast: a report of three cases and review of the literature.
     J Clin Pathol, 58(7): 775-8. [Abstract] [Full-text]
198. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
     J Clin Pathol, 58(7): 710-4. [Abstract] [Full-text]
199. Pathological diagnosis of columnar cell lesions of the breast: are there issues of reproducibility?
     J Clin Pathol, 58(7): 705-9. [Abstract] [Full-text]
200. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?
     J Clin Pathol, 58(7): 700-4. [Abstract] [Full-text]
201. Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients.
     Clin Chem, 51(7): 1093-101. [Abstract] [Full-text]
202. US correlation for MRI-detected breast lesions in women with familial risk of breast cancer.
     Clin Radiol, 60(7): 801-6. [Abstract] [Full-text]
203. Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.
     Cancer Lett, 225(2): 261-6. [Abstract] [Full-text]
204. Rapid immunohistochemistry enhances the intraoperative diagnosis of sentinel lymph node metastases in invasive lobular breast carcinoma.
     Cancer, 104(1): 14-9. [Abstract] [Full-text]
205. Improving local control with breast-conserving therapy: a 27-year single-institution experience.
     Cancer, 104(1): 20-9. [Abstract] [Full-text]
206. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
     Cancer, 104(1): 176-82. [Abstract] [Full-text]
207. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells.
     J Biol Chem, 280(26): 24428-34. [Abstract] [Full-text]
208. Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin.
     J Biol Chem, 280(26): 24363-70. [Abstract] [Full-text]
209. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma.
     Histopathology, 47(1): 82-9. [Abstract] [Full-text]
210. Comparative study of CD34, alpha-SMA and h-caldesmon expression in the stroma of gynaecomastia and male breast carcinoma.
     Histopathology, 47(1): 74-81. [Abstract] [Full-text]
211. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
     J Clin Pharm Ther, 30(4): 313-7. [Abstract] [Full-text]
212. Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life.
     Jpn J Clin Oncol, 35(6): 302-9. [Abstract] [Full-text]
213. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes.
     Jpn J Clin Oncol, 35(6): 310-5. [Abstract] [Full-text]
214. Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography.
     Radiology, 236(1): 37-46. [Abstract] [Full-text]
215. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
     Oncogene, 24(28): 4540-8. [Abstract] [Full-text]
216. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
     Oncogene, 24(28): 4531-9. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.